会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 11. 发明授权
    • Iontophoresis device
    • 离子渗透装置
    • US06643544B1
    • 2003-11-04
    • US09958602
    • 2001-10-12
    • Hirotoshi AdachiKazuya KatagaiNaruhito Higo
    • Hirotoshi AdachiKazuya KatagaiNaruhito Higo
    • A61N130
    • A61N1/30
    • The present invention provides an iontophoresis device and an energization method whereby a prostaglandin can be effectively and continuously administered via a skin or mucosa. The iontophoresis device comprises the first electrode structure (31); the second electrode structure (32); and a power supply (33) electrically connected between the first and the second electrode structures (31), (32). At least one of the first and the second electrode structures contains a prostaglandin and also stabilizing means for inhibiting hydrolysis of the prostaglandin during storage. The power supply (33) is equipped with constant current supplying means and, when both electrode structures contain a prostaglandin, also polarity inverting means. Output current from the power supply may allow the prostaglandin to be delivered to a skin or mucosa.
    • 本发明提供了一种离子电渗疗法装置和通电方法,其中前列腺素可通过皮肤或粘膜有效且连续地施用。 离子电渗装置包括第一电极结构(31); 第二电极结构(32); 和电连接在第一和第二电极结构(31),(32)之间的电源(33)。 第一和第二电极结构中的至少一个包含前列腺素以及用于在储存期间抑制前列腺素水解的稳定手段。 电源(33)配备有恒流供给装置,并且当两个电极结构都包含前列腺素时,还具有极性反转装置。 来自电源的输出电流可允许将前列腺素输送至皮肤或粘膜。
    • 15. 发明授权
    • Interface for transdermal drug administration device
    • 透皮给药装置的界面
    • US07914813B2
    • 2011-03-29
    • US10588168
    • 2005-02-02
    • Hirotoshi AdachiSeiji TokumotoNaruhito Higo
    • Hirotoshi AdachiSeiji TokumotoNaruhito Higo
    • A61F13/00
    • A61M37/0015A61M2037/0023
    • It is intended to provide an interface for a transdermal drug administration device that can supply a drug almost evenly and favorably from a plurality of projections through skin. This interface for a transdermal drug administration device has a flat plate 8. The flat plate 8 comprises a plurality of two-dimensionally arranged conical or pyramidal projections 6 capable of piercing skin and a plurality of openings 7 capable of delivering a drug which are respectively arranged in correspondence with the projections. The openings 7 are respectively arranged in proximity to their corresponding projections 6. The flat plate 8 can be made of a metal or ceramics. The ratio between the number of the openings and the number of the projections can be 1:1 to 1:2.
    • 旨在提供一种透皮给药装置的界面,其能够从多个突起通过皮肤几乎均匀且有利地供应药物。 用于透皮给药装置的该界面具有平板8.平板8包括能够刺穿皮肤的多个二维布置的锥形或棱锥形突起6和能够递送分别布置的药物的多个开口7 与预测对应。 开口7分别设置在其对应的突起6附近。平板8可以由金属或陶瓷制成。 开口数与突出数之比可以为1:1〜1:2。
    • 16. 发明申请
    • Percutaneous absorption preparation containing palonosetron
    • 含帕洛诺司琼的经皮吸收制剂
    • US20090285877A1
    • 2009-11-19
    • US12453566
    • 2009-05-14
    • Takashi YasukochiYukihisa NakaTsuyoshi EndoHirotoshi Adachi
    • Takashi YasukochiYukihisa NakaTsuyoshi EndoHirotoshi Adachi
    • A61K9/70A61K31/473
    • A61K31/473A61K9/7053A61K9/7061A61K9/7076
    • There is provided a percutaneous absorption preparation that has a simple laminated structure and a long shelf life, while maintaining excellent percutaneous absorption for palonosetron. The percutaneous absorption preparation comprises a support and a drug-containing pressure-sensitive adhesive layer formed on at least one side of the support, wherein the drug-containing pressure-sensitive adhesive layer comprises, as essential constituent components, an adhesive base, palonosetron or a pharmaceutically acceptable acid addition salt thereof, and at least one type of fatty alcohol selected from the group consisting of C6-12 straight-chain saturated alcohols, C10-22 straight-chain unsaturated alcohols, C10-22 branched alcohols and C10-15 cyclic alcohols, and the constituent components other than palonosetron or its pharmaceutically acceptable acid addition salt are carboxyl group-free components.
    • 提供了具有简单的层压结构和长的保存期限的经皮吸收制剂,同时保持帕洛诺司琼的优异的经皮吸收。 经皮吸收制剂包括在载体的至少一侧上形成的载体和含药物的压敏粘合剂层,其中药物压敏粘合剂层包含作为必要组分的组分的粘合剂基质,帕洛诺司琼或 其药学上可接受的酸加成盐和至少一种选自C 6-12直链饱和醇,C10-22直链不饱和醇,C10-22支链醇和C10-15环状脂肪醇的脂肪醇 醇,除了帕洛诺司琼或其药学上可接受的酸加成盐以外的组成成分是无羧基组分。
    • 18. 发明授权
    • Device structure for iontophoresis
    • 离子电渗法的装置结构
    • US5908400A
    • 1999-06-01
    • US878852
    • 1997-06-20
    • Naruhito HigoHirotoshi AdachiTatsuya Meno
    • Naruhito HigoHirotoshi AdachiTatsuya Meno
    • A61N1/30A61N1/32
    • A61N1/044A61N1/0436A61N1/325A61N1/0448
    • An iontophoretic device structure of the dissolution-on-use type is provided, wherein an ionized drug is transdermally or transmucosally administered into a living body. The device structure comprises (a) a non-polarizable electrode, (b) a hydrophilic, polymeric gel layer containing an ion exchange resin which is able to specifically inhibit the movement of ions dissolved out from the electrode while in use, and (c) a drug layer containing a drug in a dry condition in a drug retaining membrane, wherein when said device is in use, said drug layer is brought into contact with said hydrophilic, polymeric gel layer so that said drug in the dry condition is dissolved. A humectant may be contained in the hydrophilic, polymeric gel layer and/or the drug layer.
    • 提供了使用溶解型的离子电渗疗法器件结构,其中电离药物经皮或经粘膜施用于生物体。 该装置结构包括(a)不可极化电极,(b)含有离子交换树脂的亲水性聚合物凝胶层,其能够在使用时特异性地抑制从电极溶出的离子的移动,以及(c) 在药物保持膜中含有处于干燥状态的药物的药物层,其中当使用所述装置时,使所述药物层与所述亲水性聚合物凝胶层接触,使得干燥条件下的所述药物溶解。 保湿剂可以包含在亲水性聚合物凝胶层和/或药物层中。
    • 20. 发明授权
    • Device for iontophoresis
    • 离子电渗疗法装置
    • US07937141B1
    • 2011-05-03
    • US09958113
    • 2000-04-06
    • Kazutaka InoueHirotoshi Adachi
    • Kazutaka InoueHirotoshi Adachi
    • A61N1/30
    • A61N1/30
    • A device for iontophoresis that reduces irritation at the beginning of energization and efficiently supplies an amount of current required for drug administration in a predetermined length of time, is provided. With the device for iontophoresis, the oscillation frequency and duty cycle of a transistor 15 are adjusted at the beginning of energization, thereby controlling a back electromotive force developed across a coil 13 to gradually increase the output voltage. The microcomputer 12 controls the transistor 15 so as to receive signals from an output voltage detecting circuit that is formed of resistors 23 and 24 and an output current detecting circuit that is formed of resistors 25 and 26 and a capacitor 27, preventing an increasing of the output voltage when the detected output current reaches a limiting value, and preventing an increasing of the output current when the detected output voltage reaches a limiting value.
    • 提供一种用于离子电渗疗法的装置,其在通电开始时减少刺激,并且在预定时间长度内有效地提供药物施用所需的电流量。 利用离子电渗法的装置,在通电开始时调整晶体管15的振荡频率和占空比,由此控制在线圈13上产生的反电动势,逐渐增加输出电压。 微型计算机12控制晶体管15以接收来自由电阻器23和24形成的输出电压检测电路的信号和由电阻器25和26以及电容器27形成的输出电流检测电路,从而防止 当检测到的输出电流达到极限值时,输出电压,并且当检测到的输出电压达到极限值时防止输出电流的增加。